Table 1.
Clinical Characteristics of IBD Patients
| Disease Activity | ||||||
|---|---|---|---|---|---|---|
| Patient ID | Diagnosis | Gender | Age | Region Involved | Mayo Score (UC) or Simple Endoscopic Score (CD) | Medication |
| 1 | UC | F | 36 | Rectum | 2 | Mesalamine |
| 2 | UC | M | 40 | Ascending colon | 2 | Humira, prograf |
| 3 | UC | M | 25 | pan-UC | 3 | Humira, prograf |
| 4 | UC | M | 69 | pan-UC | 2 | Entyvio |
| 5 | CD | F | 35 | Ileum and Rectum | 12 | None |
| 6 | CD | M | 33 | Rectum | 3 | Entyvio |
| 7 | CD | F | 55 | Ileum | 4 | Mercaptopurine |
| 8 | CD | F | 43 | Colon | 0 | Azathioprine |
| 9 | CD | F | 66 | Small bowel/rectum | 3 | Humira, Prednisone |
| 10 | CD | F | 64 | Colon | 4 | Remicade |
| 11 | UC | F | 50 | Colon-pan | 3 | Mesalamine |
| 12 | UC | M | 35 | Colon-pan | 3 | Humira |
| 13 | UC | M | 28 | Small bowel, rectum | na | Remicade |
| 14 | UC | F | 42 | Colon-pan | 2 | Xeljanz |
| 15 | UC | F | 34 | Colon-pan | 0 | Sulfasalazine |
| 16 | CD | F | 27 | Left colon, rectum | 4 | Humira |
| 17 | UC | M | 52 | Pan-colon | 2 | Simponi |
| 18 | UC | F | 45 | Colon | na | None |
| 19 | CD | M | 73 | Colon | 20 | Entyvio |
| 20 | UC | F | 56 | Rectum | 2 | Mesalamine |
| 21 | CD | F | 60 | transverse/left colon | 4 | Mesalamine |
| 22 | CD | M | 71 | ileum | 6 | Vedolizumab |
| 23 | UC | F | 38 | pan-UC | 1 | Adalimumab |
| 24 | UC | F | 37 | pan-UC | 2 | Infliximab |
| 25 | CD | F | 60 | colitis | 18 | Adalimumab |
| 26 | UC | M | 40 | pan-uc | 1 | Vedolizumab |
| 27 | CD | M | 54 | ileum and colon | 11 | Ustekinumab |
| 28 | UC | F | 35 | extensive uc | 2 | Mesalamine/Enbrel |
| 29 | CD | F | 59 | left colon | 4 | Mesalamine |
| 30 | CD | M | 27 | ileum, rectum | 4 | Adalimumab |
| 31 | UC | M | 48 | pan uc | 0 | Mesalamine |
| 32 | UC | M | 37 | pan uc | 2 | Mesalamine |
| 33 | UC | M | 19 | pan uc | 2 | Mesalamine |
| 34 | UC | F | 40 | pan uc | 2 | Vedolizumab |